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Endothelial dysfunction resulting in disintegration of vascular
structure and function is a key element in the progression of
chronic kidney disease (CKD). Many risk factors—traditional
and non-traditional—are thought to have a role in the
progression and development of cardiovascular disease
(CVD) in patients with CKD. However, many risk factors await
definitive confirmation of their clinical relevance obtained
from intervention trials. Moreover, the investigation of the
relative contribution of these factors to the twin-risk problem
of CVD and progression in patients with CKD is one of the
most important future challenges for nephrologists.
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The endothelium is the innermost (single) cell lining of all
blood vessels within the body; however, endothelial cell
phenotypes may vary considerably in structure and function
within different vascular regions.1,2 For example, even
between glomerular and peritubular capillaries, endothelial
function differs significantly because of their high specializa-
tion. In this respect, the integrity of the endothelial cell layer
has a pivotal role in many aspects of vascular function,
for example, control of vasomotor tone and permeability,
the latter being of paramount importance particularly
for glomerular capillaries. However, despite the functional
diversity of endothelial cells in different vascular compart-
ments, a key common feature is their ability to synthesize and
secrete a variety of factors impinging upon vascular tone and
on vascular protection.3
The endothelium produces a range of vasorelaxant factors,
the most significant and well characterized of which is
nitric oxide (NO). NO is a fundamental gas that stimulates
relaxation of vascular smooth muscle cells and inhibits
their proliferation, and prevents leukocyte attachment
and migration into the arterial wall, and platelet adhesion
and aggregation to the endothelium. Prostacyclin and
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endothelium-derived hyperpolarizing factor are also impor-
tant endothelium-derived vasorelaxants, with the latter
contributing to endothelium-dependent vasodilatation in
resistant arteries. The vast majority of studies on endothelial
dysfunction have concentrated on the mechanisms respon-
sible for the decreased bioavailability of NO, which may
result from a decrease in NO production, from a decrease in
activation of guanylyl cyclase, and/or from an increase in NO
degradation. A decrease in NO production may result from
reduced availability of substrates and cofactors for NO
synthases, such as L-arginine or tetrahydrobiopterin; from a
decreased expression of endothelial NO synthase (eNOS) or
from a decreased activation of eNOS, such as phosphoryla-
tion of the enzyme or interactions with proteins (for
example, heat shock protein 90 or calmodulin); or from
high levels of endogenous inhibitors of eNOS, such as
asymmetric dimethylarginine in particular. Finally, reduced
NO bioavailability levels may be caused by the binding of NO
to hemoglobin or from oxidative stress, which gives rise to
peroxynitrite, a vasculotoxic substance. On the other hand,
endothelial cells produce several vasoconstrictors, including
endothelin-1, cyclooxygenase-derived prostanoids, reactive
oxygen species, dinucleotide uridine adenosine tetrapho-
sphate, and angiotensin II. When the balance between
endothelium-derived vasorelaxants and vasoconstrictors is
altered, endothelial dysfunction ensues.
Because of its enormous surface area within the body, the
endothelium has an important role in major diseases such as
hypertension and diabetes. In these conditions, the endothe-
lium undergoes functional and structural alterations, even-
tually resulting in loss of its role as a protective barrier.
Endothelial dysfunction is the earliest—merely functional—
step in the cascade of events leading to atherosclerosis, and
the fundamental feature of this condition is impaired NO
bioavailability.4,5 If perpetuated long enough, dysfunction of
endothelial cells is followed by their apoptosis, which can
finally result in functional and structural disintegration of the
endothelial cell layer. This is paralleled by vascular ‘micro-
inflammation’ as a result of leukocyte and thrombocyte
activation and adhesion, which further accelerates the vessel
wall damage.6 This process leads to progressive atherosclero-
tic disease in larger vessels and/or complete disruption of
smaller (tissue) blood vessels. Finally, vessel disappearance
(‘vascular rarefaction’) may terminate in malperfusion and
hypoxia of tissues and whole organs. For this reason,
hypertension and diabetes are recognized not only as main
(cardio) vascular risk factors resulting in death due to
atherosclerotic complications but also as the most important
conditions leading to end-stage kidney disease as a
consequence of progressive glomerulosclerosis and rarefac-
tion of postglomerular capillaries. Here, the kidney pays the
definite price for its generous vascular supply as the organ
with the largest total endothelial surface area.
In patients with chronic kidney disease (CKD), endo-
thelial dysfunction may have a dual role. On the one hand,
it is a crucial step in the development of cardiovascular
disease (CVD). On the other hand, activation, dysfunction,
and disintegration of endothelial cells in glomerular capil-
laries and particularly in the capillaries that nurture the renal
medulla pave the way for CKD progression. It has become
clear from experimental studies that vascular rarefaction in
this capillary system is a crucial step toward renal tissue
hypoxia and kidney damage.7 A myriad of factors are thought
to be involved in the process of endothelial dysfunction
and disintegration, which, through further steps of vascular
injury, finally results in end-stage CVD and/or CKD.
However, the competing twin risk of patients with CKD—
development of CVD and/or CKD progression—is not well
elucidated. In other words, we do not understand yet why
some patients progress to end-stage kidney disease without
significant cardiovascular events, whereas others die before
reaching terminal renal failure due to complications of severe
(larger-vessel) atherosclerosis. Furthermore, in patients with-
out CKD, a large body of evidence supports the hypothesis
that endothelial dysfunction and microinflammation repre-
sent major promoters for atherosclerosis and independently
predict the risk of future cardiovascular events,8–10 whereas in
patients with CKD firm evidence for this relationship has not
been provided so far. Finally, the relationship between
endothelial dysfunction of peripheral and renal vessels in
CKD patients has not been explored in detail, and the
prognostic value of endothelial dysfunction in the renal
circulation for CKD progression is almost unknown.
Here, the assessment of endothelial dysfunction is mostly
restricted to functional tests such as the response of the renal
(micro)circulation to vasodilator and/or vasoconstrictor
stimuli, for example, NO inhibitors or angiotensin II—
usually assessed by a change in the para-aminohippurate
clearance. Furthermore, although the number of studies
focusing on NO bioavailability and disturbed NO vasoregu-
lation in CKD is on the rise, we still lack studies looking at
the balance between vasorelaxant and vasoconstrictor factors
rather than on single-factor perturbation.
Many risk factors—traditional and non-traditional—are
thought to have a more or less important role in the
development of CVD and progression in CKD patients
(Table 1). Some of these are established cardiovascular risk
factors, for example, hypertension and smoking, and their
successful treatment or cessation results in reduced cardio-
vascular events and in slowing down progression. Others only
seem to identify patients at risk, that is, they are only markers
of risk, such as high serum homocysteine. In patients with
progressive CKD, the issue is further complicated because of
the appearance of uremia-specific risk factors with the
potential of contributing to endothelial and vascular
dysfunction and damage (Table 2). In this respect, many
novel putative ‘biomarkers’ of risk—either for CVD or for
progression—have been discovered in the last two decades.
However, for many of them causality has not been proven yet,
even in experimental studies, and for almost all of them the
definitive confirmation of their pathophysiological role and
clinical relevance from intervention trials in CKD patients is
Kidney International Supplements (2011) 1, 6–9 7
D Fliser et al.: Endothelial function and CKD min i rev iew
still pending. This will certainly be one of the most important
future challenges in the field of (cardio)vascular research in
nephrology (Figure 1). In addition, the relative contribution
of these (risk) factors and markers to the twin risk of CVD
and progression in CKD patients has not been appropriately
investigated so far. In the face of the many discovered
putative risk factors and markers in recent years, the above
questions may be of greater importance than the search for
further biomarkers with uncertain significance for CVD and
progression in patients with CKD.
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Table 2 | CKD-specific risk factors and putative ‘biomarkers’
for cardiovascular disease and for progression in patients
with CKD
Volume overload/increased natriuretic peptides (e.g., NT-proBNP)
Proteinuria
Increased parathormone and calcium/phosphate product
Increased fibroblast growth factor 23
Reduced vitamin D
Acidosis
Anemia
Hypoalbuminemia
Reduced fetuin A and other inhibitors of calcification
Increased asymmetric dimethylarginine and other endogenous NO
inhibitors
Increased high-sensitivity C-reactive protein and other inflammatory
markers
Oxidative stress/increased production of reactive oxygen species
Increased susceptibility to infections
?
Abbreviations: CKD, chronic kidney disease; NO, nitric oxide.
Some of these factors are present also in patients without CKD, but they
accumulate/disperse significantly with declining kidney function.
Table 1 | Risk factors and putative ‘biomarkers’ for
cardiovascular disease and progression in patients with
chronic kidney disease
Traditional
Age
Gender (male)
Family history (genetic background)
High blood pressure
Obesity/physical inactivity
Hyper- and dyslipidemia
Increased fibrinogen/other coagulation disorders
Hyperinsulinemia
Glucose intolerance/hyperglycemia/diabetes
Smoking
?
Non-traditional
Albuminuria/proteinuria
Increased homocysteine
Increased asymmetric dimethylarginine and other endogenous
nitric oxide inhibitors
Increased high-sensitivity C-reactive protein and other inflammatory
markers
Increased adhesion molecules
Oxidative stress/increased production of reactive oxygen species
Increased fatty acids/high lipoprotein a
Increased advanced glycation endproducts
Reduced adiponectin and/or increased leptin
Reduced vitamin D
Increased natriuretic peptides (e.g., NT-proBNP)
?
K Definition of endothelial dysfunction of the renal
(micro)circulation.
K Studying the relationship between peripheral and renal
endothelial dysfunction in patients with chronic kidney
disease (CKD) across the whole range of renal function
and taking into account proteinuria and the nature of
kidney disease.
K Testing the association of some CKD-specific factors such
as low vitamin D levels and metabolic acidosis with
endothelial dysfunction; performing intervention studies
to explore whether these links are causal in nature.
K Testing the predictive power of peripheral and renal
endothelial dysfunction for future cardiovascular events
and for progression in patients with CKD.
K Characterization of risk factors versus risk markers for endothelial
dysfunction and validation of risk factors for future events
in intervention trials.
K Clarification of the relative contribution of risk factors for
cardiovascular disease versus renal disease progression in
patients with CKD.
K Validation of risk markers with respect to their ability to
identify individuals at risk.
K Identification of novel risk factors and markers for
cardiovascular disease and for progression in patients
with CKD.
K Studying endothelial function in patients with CKD and
patients with cardiovascular diseases by considering
the balance of vasoconstrictors and vasodilators made
up by the endothelium.
Figure 1 | Some open questions on the role of endothelium in
the cardio-renal connection.
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